Beyaz is owned by Bayer Hlthcare.
Beyaz contains Drospirenone; Ethinyl Estradiol; Levomefolate Calcium.
Beyaz has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Beyaz are:
Beyaz was authorised for market use on 24 September, 2010.
Beyaz is available in tablet;oral dosage forms.
Beyaz can be used as prevention of pregnancy.
The generics of Beyaz are possible to be released after 08 February, 2030.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Jul, 2022
(6 months ago) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(11 months ago) | |
US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(7 years from now) |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 24 September, 2010
Treatment: Prevention of pregnancy
Dosage: TABLET;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic